Wednesday, April 04, 2018—The first patients to complete the phase 2 clinical trial of AMX0035 (Amylyx; Cambridge, MA), a combination of phenylbutyrate (PB) and tauroursodeoxycholic acid (TUDCA), for a…
Wednesday, March 21, 2018—As published in today’s issue of the journal Neuron, researchers have identified specific mutations in the kinesin family gene, KIF5A, that cause amyotrophic lateral scl…
Friday, March 16, 2018—Already approved in 51 countries for some immune deficiencies, subcutaneous immune globulin (IG) (Hizentra; King of Prussia, PA) has now been approved by the Food and Drug Adm…
Thursday, March 15, 2018—The results of a phase 2 proof-of concept study of AMO-02, an investigational therapy for childhood-onset myotonic dystrophy type 1 were presented at the Muscular Dystrophy As…
Tuesday, March 13, 2018—Approval has been granted by the Israel Ministry of Health’s Supreme Committee for Kadimastem (NessZiona, Israel) to immediately begin a phase I/IIa clinical trial of th…
Thursday, March 01, 2018—In a transatlantic collaboration, Mylan N.V. (Pittsburgh, Pennsylvania) and Revance Therapeutics, Inc. (Hertsfordshire, England) have reached an agreement to collaborate on th…
Wednesday, February 21, 2018—In findings published this week in Nature Neuroscience, researchers Krista J. Spiller, Clark R. Restrepo, Tahiyana Khan, and others described creation of a mouse model of amyo…
Wednesday, February 07, 2018—Brainstorm Cell Therapeutics Inc. announced that they will present results from the NurOwn phase 2 randomized, double-blind, placebo-controlled study, showing ALSFRS-R subgrou…
